Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

Novartis Pharmaceuticals · 2016
ClinicalTrials.gov · Datasets · License: Public Domain · 2016
Open Source ↗
myelofibrosis with high molecular risk mutations, early myelofibrosis, high molecular risk mutations., ruxolitinib, inc424, high molecular risk mutations, hmr, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 829483
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.